Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics by McCormack, Clare P, Goethals, Olivia, Goeyvaerts, Nele, Woot de Trixhe, Xavier D, Geluykens, Peggy, Borrenberghs, Doortje, Ferguson, Neil M, Ackaert, Oliver, Dorigatti, Ilaria

Get full text

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy by Burke, G. A. Amos, Beishuizen, Auke, Bhojwani, Deepa, Burkhardt, Birgit, Minard-Colin, Véronique, Norris, Robin E., Kabickova, Edita, Pinarli, F. Guclu, Tacyildiz, Nurdan, Howes, Angela, Jong, Jan de, Liu, Grace, Nottage, Kerri, Salman, Mariya, Trixhe, Xavier Woot de, Cairo, Mitchell

Get full text

A Robust Simulator for Physiologically Structured Population Models by Van Dyck, Michiel, de Trixhe, Xavier Woot, Vermeulen, An, Vanroose, Wim

Get full text

Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy by Woot de Trixhe, Xavier, Krzyzanski, Wojciech, Vermeulen, An, Perez‐Ruixo, Juan José

Get full text

A quantitative systems pharmacology model for acute viral hepatitis B by Asín-Prieto, Eduardo, Parra-Guillen, Zinnia P., Gómez Mantilla, José David, Vandenbossche, Joris, Stuyckens, Kim, de Trixhe, Xavier Woot, Perez-Ruixo, Juan José, Troconiz, Iñaki F.

Get full text

The method of averaging applied to pharmacokinetic/pharmacodynamic indirect response models by Dunne, Adrian, de Winter, Willem, Hsu, Chyi-Hung, Mariam, Shiferaw, Neyens, Martine, Pinheiro, José, de Trixhe, Xavier Woot

Get full text

Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB) by T’jollyn, Huybrecht, Goeyvaerts, Nele, Kakuda, Thomas, Sandra, Louis, Ogawa, Tetsuro, Vandenbossche, Joris J, de Trixhe, Xavier Woot, Lenz, Oliver, Kalmeijer, Ronald, Biermer, Michael, Perez Ruixo, Juan Jose, Ackaert, Oliver

Get full text

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies by Marostica, Eleonora, Sukbuntherng, Juthamas, Loury, David, de Jong, Jan, de Trixhe, Xavier Woot, Vermeulen, An, De Nicolao, Giuseppe, O’Brien, Susan, Byrd, John C., Advani, Ranjana, McGreivy, Jesse, Poggesi, Italo

Get full text

Dynamic population pharmacokinetic–pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice‐daily dosing of canagl... by Winter, Willem, Dunne, Adrian, Trixhe, Xavier Woot, Devineni, Damayanthi, Hsu, Chyi‐Hung, Pinheiro, Jose, Polidori, David

Get full text

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics by Clare P. McCormack, Olivia Goethals, Nele Goeyvaerts, Xavier D. Woot de Trixhe, Peggy Geluykens, Doortje Borrenberghs, Neil M. Ferguson, Oliver Ackaert, Ilaria Dorigatti

Get full text

Immune network for viral hepatitis B: Topological representation by Asín-Prieto, Eduardo, Parra-Guillen, Zinnia P., Mantilla, José David Gómez, Vandenbossche, Joris, Stuyckens, Kim, de Trixhe, Xavier Woot, Perez-Ruixo, Juan José, Troconiz, Iñaki F.

Get full text

Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies by Poggesi, Italo, Sardu, Maria Luisa, Marostica, Eleonora, Sukbuntherng, Juthamas, Chang, Betty Y., Jong, Jan de, Trixhe, Xavier Woot de, Vermeulen, An, Nicolao, Giuseppe De, O'Brien, Susan Mary, Byrd, John C, Advani, Ranjana H, James, Danelle Frances, Deraedt, William, Beaupre, Darrin, Wang, Michael

Get full text